MET Pipeline
NuBiyota is developing a pipeline of multi-strain microbiome therapeutic composition candidates to treat a range of medical conditions and diseases, using its proprietary Microbial Ecosystem Therapeutics platform.
| Asset | Indication | Pre-clinical | IND | Ph1 | Ph2 | Ph3 |
Immuno-oncology |
||||||
| MET-4 | PD-1 combo-therapy | |||||
Metabolic Disease |
||||||
| MET-3 | Hypertriglyceridemia (HTG) | |||||
GI Disorder/rCDI (recurrent Clostridioides Difficile Infection) |
||||||
| MET-2 | Ulcerative colitis (UC) | |||||
| MET-2 | Recurrent C.difficile infection (rCDI) | |||||
CNS Disease |
||||||
| MET-2 | Depression, Anxiety | |||||
The MET 3 phase II study is in the US all other studies are done in Canada.